Tri Locum Partners
Latest statistics and disclosures from Tri Locum Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are JNJ, DHR, LLY, UTHR, ASND, and represent 50.34% of Tri Locum Partners's stock portfolio.
- Added to shares of these 10 stocks: DHR (+$79M), LLY (+$68M), JNJ (+$62M), BSX (+$50M), TEVA (+$45M), IONS (+$44M), NUVL (+$31M), DXCM (+$28M), ASND (+$19M), DNTH (+$18M).
- Started 7 new stock positions in DXCM, LLY, BSX, NUVL, TEVA, DHR, IONS.
- Reduced shares in these 10 stocks: , SLNO (-$31M), , VERA (-$20M), AXSM (-$17M), KRRO (-$16M), XENE (-$15M), AVDL (-$11M), STVN (-$8.6M), TARS (-$7.1M).
- Sold out of its positions in ABBV, KRRO, MRK, PRAX, SLNO, TARS, XENE, BHVN, AVDL, STVN.
- Tri Locum Partners was a net buyer of stock by $261M.
- Tri Locum Partners has $770M in assets under management (AUM), dropping by 77.02%.
- Central Index Key (CIK): 0001826434
Tip: Access up to 7 years of quarterly data
Positions held by Tri Locum Partners consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Tri Locum Partners
Tri Locum Partners holds 15 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Johnson & Johnson (JNJ) | 16.2 | $125M | +99% | 603k | 206.95 |
|
| Danaher Corporation (DHR) | 10.3 | $79M | NEW | 347k | 228.92 |
|
| Eli Lilly & Co. (LLY) | 8.8 | $68M | NEW | 63k | 1074.68 |
|
| United Therapeutics Corporation (UTHR) | 7.7 | $59M | 121k | 487.25 |
|
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 7.3 | $57M | +51% | 265k | 213.24 |
|
| Madrigal Pharmaceuticals (MDGL) | 6.5 | $50M | +27% | 86k | 582.34 |
|
| Boston Scientific Corporation (BSX) | 6.4 | $50M | NEW | 521k | 95.35 |
|
| Teva Pharmaceutical Inds Sponsored Ads (TEVA) | 5.8 | $45M | NEW | 1.4M | 31.21 |
|
| Ionis Pharmaceuticals (IONS) | 5.7 | $44M | NEW | 557k | 79.11 |
|
| Vera Therapeutics Cl A (VERA) | 5.3 | $41M | -32% | 806k | 50.64 |
|
| Axsome Therapeutics (AXSM) | 4.8 | $37M | -30% | 202k | 182.64 |
|
| Argenx Se Sponsored Adr (ARGX) | 4.1 | $32M | -13% | 38k | 840.95 |
|
| Nuvalent Inc-a (NUVL) | 4.0 | $31M | NEW | 307k | 100.59 |
|
| Dex (DXCM) | 3.6 | $28M | NEW | 422k | 66.37 |
|
| Dianthus Therapeutics (DNTH) | 3.3 | $26M | +240% | 622k | 41.21 |
|
Past Filings by Tri Locum Partners
SEC 13F filings are viewable for Tri Locum Partners going back to 2020
- Tri Locum Partners 2025 Q4 filed Feb. 17, 2026
- Tri Locum Partners 2025 Q3 filed Nov. 14, 2025
- Tri Locum Partners 2025 Q2 filed Aug. 14, 2025
- Tri Locum Partners 2025 Q1 filed May 14, 2025
- Tri Locum Partners 2024 Q4 filed Feb. 14, 2025
- Tri Locum Partners 2024 Q3 filed Nov. 14, 2024
- Tri Locum Partners 2024 Q2 filed Aug. 14, 2024
- Tri Locum Partners 2024 Q1 filed May 15, 2024
- Tri Locum Partners 2023 Q4 filed Feb. 14, 2024
- Tri Locum Partners 2023 Q3 filed Nov. 14, 2023
- Tri Locum Partners 2023 Q2 filed Aug. 14, 2023
- Tri Locum Partners 2023 Q1 filed May 15, 2023
- Tri Locum Partners 2022 Q4 filed Feb. 14, 2023
- Tri Locum Partners 2022 Q3 filed Nov. 14, 2022
- Tri Locum Partners 2022 Q2 filed Aug. 15, 2022
- Tri Locum Partners 2022 Q1 filed May 16, 2022